BSX: Shares Will Rise On Earnings Strength And Multi Year Execution Momentum

Analysts nudged their average price target for Boston Scientific modestly higher, toward the low to mid $130 range, citing the company’s Q3 beat, accelerating Watchman adoption, confidence in multi year guidance, and a robust growth pipeline supported by strategic acquisitions like Nalu, despite some cautions on valuation and longer term growth moderation.

Analyst Commentary

Analyst reaction to Boston Scientific's latest results and strategic updates has been predominantly positive, with several firms raising price targets and reiterating favorable ratings, while a minority voice has started to flag valuation and medium term growth risks.

Bullish Takeaways

• Bullish analysts highlight the Q3 earnings beat and accelerating Watchman adoption as evidence that Boston Scientific can continue to outgrow large cap MedTech peers on both sales and EPS.
• Several models have been revised higher following updated 2025 guidance and a new three year plan that targets around 10 percent organic growth, which reinforces confidence in multi year execution.
• The Nalu acquisition is viewed as another value accretive deal that deepens the company’s presence in peripheral nerve stimulation and strengthens the long term innovation pipeline.
• Improved sentiment around electrophysiology performance, with fears of share loss easing after the latest print, supports the view that Boston Scientific can sustain an attractive growth and margin profile.

Bearish Takeaways

• Bearish analysts argue that the stock screens expensive versus peers, with much of the above peer growth narrative already reflected in current valuation and limiting near term upside.
• There is growing concern that sales growth could decelerate in 2026 relative to 2025, which raises questions about how long double digit expansion can be maintained without pressure on the multiple.
• Some cautious views focus on the risk that increasingly ambitious long range targets and a more acquisition driven pipeline raise the bar for consistent execution.
• Incremental target hikes in the low to mid $130 range are characterized as modest, which suggests a more balanced risk reward skew even among otherwise constructive voices.

What's in the News

• Truist raised its Boston Scientific price target to $130 from $129 and reiterated a Buy rating after a solid Q3 beat, highlighting accelerating Watchman growth and confidence in upside to higher guidance (Truist research note).
• Boston Scientific issued new guidance for Q4 2025, forecasting reported net sales growth of approximately 14.5% to 16.5%, organic growth of 11% to 13%, and GAAP EPS of $0.48 to $0.52 (Corporate guidance filing).
• For full year 2025, the company guided to about 20% reported net sales growth and approximately 15.5% organic growth, with GAAP EPS expected in a range of $1.97 to $2.01 (Corporate guidance filing).
• The company reported no share repurchases in the July 1 to September 30, 2025 tranche, leaving the previously authorized buyback program effectively unused in the period (Buyback tranche update).

Valuation Changes

• Discount Rate: fallen slightly from 7.89% to 7.88%, implying a marginally lower required return on equity.
• Revenue Growth: effectively unchanged at about 11.05%, indicating stable long term top line growth assumptions.
• Net Profit Margin: effectively unchanged at about 19.34%, reflecting steady expectations for underlying profitability.
• Future P/E: edged down slightly from 46.56x to 46.55x, signaling a negligible adjustment to the long term earnings multiple.